...approval, which includes a black box warning describing risks of fetal harm, marks the first for an sGC...
...neu) – Epidermal growth factor receptor 2PD-1 (PDCD1; CD279) – Programmed cell death 1sGC – Soluble guanylate cyclase Stephen...

...two other mechanisms —cadiac myosin activation and sGC...
...a tough sell to either regulators or payers.sGC...
...advanced of three molecules that activate the NO-sGC-cGMP...

...of pulmonary artery walls. The existing drugs -- prostacyclins, endothelin receptor antagonists, PDE-5 inhibitors and sGC...
...receptor type II; NT-proBNP - N-terminal pro-brain natriuretic peptide; PDE-5 (PDE-5A) - Phosphodiesterase-5; sGC - Soluble guanylate cyclase Sandi...

...chronic heart failure with reduced ejection fraction (HFrEF). Merck & Co. Inc. (NYSE:MRK) said the sGC...
...AG (NYSE:NVS; SIX:NOVN) at baseline. Merck and Bayer AG (Xetra:BAY) are co-developing vericiguat and other sGC-targeted...
...intravenous diuretic for heart failure without hospitalization. The VICTORIA data comes just weeks after another sGC...

...Therapeutics Inc. (NASDAQ:CYCN) shares fell $10.68 (80%) to $2.75 after the company announced its lead soluble guanylate cyclase (sGC)...
...spun out of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) in April with a pipeline of candidates targeting sGC...
...months, Cyclerion expects additional data from its other sGC pipeline programs, including olinciguat, a vascular sGC...

...sGC stimulator praliciguat could help treat NASH. In liver samples from patients, levels of an sGC...
...than in non-fibrotic tissue. In a rat model of NASH, praliciguat increased levels of cGMP, sGC's...
...a marker of liver fibrosis. Next steps by Cyclerion Therapeutics Inc. include developing a liver-specific sGC...

...new preclinical data in hand, Ironwood-spinout Cyclerion is making the case for extending its lead sGC...
...Inc. (NASDAQ:IRWD) in April with a pipeline of five soluble guanylate cyclase (sGC) programs, including praliciguat, a systemic sGC...
...mouse model of diet-induced NASH and in rats with NASH. Wright said the data validate sGC...

...Cyclerion Planning $175M Private Placement" ). Cyclerion Therapeutics Inc. (NASDAQ:CYCN) has a pipeline of five soluble guanylate cyclase (sGC)...
...its gastrointestinal business (see "Splitting Ironwood" ). Mary Romeo, Staff Writer IW-6463 olinciguat (IW-1701) Praliciguat, IW-1973 Cyclerion Therapeutics Inc. Ironwood Pharmaceuticals Inc. Soluble guanylate cyclase (sGC)...

...Therapeutics Inc. (NASDAQ:CYCN) raised $175 million in a private placement. The company’s pipeline comprises five soluble guanylate cyclase (sGC)...

...become president of Cyclerion; both will become members of Cyclerion's board. Cyclerion will have five soluble guanylate cyclase (sGC)...
...26. Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Cyclerion Therapeutics Inc., Cambridge, Mass. Hongjiang Li IW-1701 IW-6463 Praliciguat, IW-1973 Ironwood Pharmaceuticals Inc. Soluble guanylate cyclase (sGC)...